Biomed Lublin with new contract to introduce Onko BCG in Germany and Switzerland

Biomed Lublin terminated the earlier and concluded a new contract with Apogepha Arzneimittel. Its aim is to allow the drug Onko BCG on the markets of Germany and Switzerland, the company said.

"Apogepha Arzneimittel will be responsible for the drug registration process in Germany and Switzerland. The contract was concluded for 10 years. Under this agreement, each year the German company will present a rolling plan for the next 12 months, which, after confirmation by…